Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent

Part of paid clinical trials in Vestavia Hills, Alabama.

Sponsor
Novo Nordisk A/S
Study ID
NCT01511198
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    Injected subcutaneously once daily
  • metformin — DRUG
    1000 mg twice daily, administered orally

Study Details

This trial is conducted in the United States of America (USA). The aim of this trial is to determine the dose-response relationship for body weight and five escalating doses of NNC 90-1170 (liraglutide) in subjects with type 2 diabetes previously treated with an oral hypoglycemic agent (OHA).

Key Dates

Start date
Feb 28, 2001
Status verified
Jan 2017
Primary completion
Oct 31, 2001
Completion
Oct 31, 2001

Study Design

Enrollment
223 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: 0.045 mg
  • Experimental: 0.225 mg
  • Experimental: 0.45 mg
  • Experimental: 0.60 mg
  • Experimental: 0.75 mg
  • Active Comparator: Met

Primary Outcome Measure

Body weight

Locations (39)

FacilityCityStateZIPSite coordinators
Novo Nordisk Investigational SiteVestavia HillsAlabama35209-
Novo Nordisk Investigational SiteTucsonArizona85719-
Novo Nordisk Investigational SiteCarlisleArkansas72024-
Novo Nordisk Investigational SiteJonesboroArkansas72401-
Novo Nordisk Investigational SiteAlhambraCalifornia91801-
Novo Nordisk Investigational SiteMission ViejoCalifornia92691-
Novo Nordisk Investigational SiteWalnut CreekCalifornia94598-
Novo Nordisk Investigational SiteTrumbullConnecticut06611-
Novo Nordisk Investigational SiteJacksonvilleFlorida32216-
Novo Nordisk Investigational SiteMelbourneFlorida32901-
Novo Nordisk Investigational SiteMiamiFlorida33156-
Novo Nordisk Investigational SiteOcalaFlorida34471-
Novo Nordisk Investigational SitePembroke PinesFlorida33024-
Novo Nordisk Investigational SiteSt. PetersburgFlorida33702-
Novo Nordisk Investigational SiteTitusvilleFlorida32796-
Novo Nordisk Investigational SiteWest Palm BeachFlorida33401-
Novo Nordisk Investigational SiteChicagoIllinois60607-
Novo Nordisk Investigational SiteSpringfieldIllinois62711-
Novo Nordisk Investigational SiteWorcesterMassachusetts01605-
Novo Nordisk Investigational SiteDuluthMinnesota55805-
Novo Nordisk Investigational SiteSt LouisMissouri63117-
Novo Nordisk Investigational SiteSt LouisMissouri63141-
Novo Nordisk Investigational SiteNorth PlainfieldNew Jersey07060-
Novo Nordisk Investigational SiteCharlotteNorth Carolina28277-
Novo Nordisk Investigational SiteDurhamNorth Carolina27710-
Novo Nordisk Investigational SiteOklahoma CityOklahoma73104-
Novo Nordisk Investigational SiteChattanoogaTennessee37404-
Novo Nordisk Investigational SiteCorpus ChristiTexas78404-
Novo Nordisk Investigational SiteDallasTexas75230-
Novo Nordisk Investigational SiteDallasTexas75246-
Novo Nordisk Investigational SiteSan AntonioTexas78209-
Novo Nordisk Investigational SiteSan AntonioTexas78229-
Novo Nordisk Investigational SiteSalt Lake CityUtah84132-
Novo Nordisk Investigational SiteRichmondVirginia23294-
Novo Nordisk Investigational SiteEdmondsWashington98026-7610-
Novo Nordisk Investigational SiteEdmondsWashington98026-
Novo Nordisk Investigational SiteRentonWashington98057-
Novo Nordisk Investigational SiteTacomaWashington98405-
Novo Nordisk Investigational SiteCharlestonWest Virginia25301-

Find similar trials in Vestavia Hills, AL

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Novo Nordisk Investigational Site· Vestavia Hills, ALNovo Nordisk Investigational Site· Tucson, AZNovo Nordisk Investigational Site· Carlisle, ARNovo Nordisk Investigational Site· Jonesboro, ARNovo Nordisk Investigational Site· Alhambra, CANovo Nordisk Investigational Site· Mission Viejo, CA

Related Studies